Close Menu

NEW YORK – Philadelphia-based Carisma Therapeutics on Thursday said it has completed a Series B equity financing round, in which it raised $47 million in gross proceeds that it will us to advance its macrophage-based cell therapy pipeline and discovery programs.

The funding round was led by Symbiosis II and included the participation of new investors Solasta Ventures and Livzon Pharmaceutical Group, as well as existing investors AbbVie Ventures, HealthCap, Wellington Partners, IP Group, TPG Biotech, Agent Capital, and MRL Ventures Fund.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.